(R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone manufacturers
- OR-1896
-
- $93.00 / 1mg
-
2024-11-20
- CAS:220246-81-1
- Min. Order:
- Purity: 99.51%
- Supply Ability: 10g
- OR-1896
-
- $93.00 / 1mg
-
2024-11-20
- CAS:220246-81-1
- Min. Order:
- Purity: 99.51%
- Supply Ability: 10g
|
| | (R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone Basic information |
| Product Name: | (R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone | | Synonyms: | (R)-N-[4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-acetamide;OR-1896;(R)-N-(4-(4-Methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide;Acetamide, N-[4-[(4R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]-;(R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-p;13C,2H3]-Levosimendan metabolite;OR 1896,OR1896;(R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone | | CAS: | 220246-81-1 | | MF: | C13H15N3O2 | | MW: | 245.28 | | EINECS: | | | Product Categories: | Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Aromatics;Heterocycles | | Mol File: | 220246-81-1.mol |  |
| | (R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone Chemical Properties |
| Melting point | 224-226°C | | density | 1.27±0.1 g/cm3(Predicted) | | storage temp. | -20°C Freezer | | solubility | Acetone (Slightly), DMSO (Slightly), Methanol (Slightly) | | form | Solid | | pka | 13.67±0.60(Predicted) | | color | Pale Yellow to Light Yellow | | CAS DataBase Reference | 220246-81-1 |
| | (R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone Usage And Synthesis |
| Chemical Properties | Pale Yellow Solid | | Uses | A metabolite of Levosimendan (L378000). | | Definition | ChEBI: OR-1896 is an anilide and a member of acetamides. | | in vivo | During the metabolism of Levosimendan approximately 5% of the drug is converted to the metabolite OR-1855 in the large intestine, and then acetylated in the liver to form the active metabolite OR-1896. Binding to plasma proteins is 98% for Levosimendan but only 40% for OR-1896. Unlike Levosimendan, which has an elimination half-life of 1-1.5 h, the half-life of OR-1896 is about 75 to 80 h allowing cardiovascular effects to persist up to 7 to 9 days after discontinuation of a 24-hour infusion of levosimendan. The pharmacokinetic of the parent drug is unaltered in subjects with severe renal impairment or with moderate hepatic impairment, whereas the elimination of its metabolites (OR-1896) can be prolonged[1]. | | IC 50 | PDE3/PDE Ⅲ; K+ Channel; Drug Metabolite |
| | (R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone Preparation Products And Raw materials |
|